Results 151 to 160 of about 4,440 (296)
Preclinical models for evaluating psychedelics in the treatment of major depressive disorder
British Journal of Pharmacology, EarlyView.Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander +5 more
wiley +1 more source
Values and ethics for implementation fidelity and integrity of public health policy in a multipolar world with conflicting value systems. [PDF]
J Public Health (Oxf)Mfutso Bengo J, Mfutso Bengo E.
europepmc +1 more source
Psychedelics, entactogens and psychoplastogens for depression and related disorders
British Journal of Pharmacology, EarlyView.Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley +1 more source
Kinesin-4 optimizes microtubule orientations for responsive tip growth guidance in moss. [PDF]
J Cell Biol, 2023 de Keijzer J +4 more
europepmc +1 more source
British Journal of Pharmacology, EarlyView.Abstract Background and Purpose Ventricular fibrillation (VF) in coronary heart disease accounts for up to 70% of sudden cardiac death. We examined whether diltiazem N‐oxide (DNO) has ischaemia‐selective antiarrhythmic activity. Experimental Approach Randomised and blinded experiments were performed in rat isolated hearts and in anaesthetised rats to ...
Louise M. Hesketh +5 more
wiley +1 more source
A MademoiseLLE domain binding platform links the key RNA transporter to endosomes. [PDF]
PLoS Genet, 2022 Devan SK +10 more
europepmc +1 more source